Literature DB >> 24419970

PTG protein depletion rescues malin-deficient Lafora disease in mouse.

Julie Turnbull1, Jonathan R Epp, Danielle Goldsmith, Xiaochu Zhao, Nela Pencea, Peixiang Wang, Paul W Frankland, Cameron A Ackerley, Berge A Minassian.   

Abstract

Ubiquitin ligases regulate quantities and activities of target proteins, often pleiotropically. The malin ubiquitin E3 ligase is reported to regulate autophagy, the misfolded protein response, microRNA silencing, Wnt signaling, neuronatin-mediated endoplasmic reticulum stress, and the laforin glycogen phosphatase. Malin deficiency causes Lafora disease, pathologically characterized by neurodegeneration and accumulations of malformed glycogen (Lafora bodies). We show that reducing glycogen production in malin-deficient mice by genetically removing PTG, a glycogen synthesis activator protein, nearly completely eliminates Lafora bodies and rescues the neurodegeneration, myoclonus, seizure susceptibility, and behavioral abnormality. Glycogen synthesis downregulation is a potential therapy for the fatal adolescence onset epilepsy Lafora disease.
© 2014 Child Neurology Society/American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24419970     DOI: 10.1002/ana.24104

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  39 in total

Review 1.  Glycogen phosphorylation and Lafora disease.

Authors:  Peter J Roach
Journal:  Mol Aspects Med       Date:  2015-08-13

2.  Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.

Authors:  M Kathryn Brewer; Annette Uittenbogaard; Grant L Austin; Dyann M Segvich; Anna DePaoli-Roach; Peter J Roach; John J McCarthy; Zoe R Simmons; Jason A Brandon; Zhengqiu Zhou; Jill Zeller; Lyndsay E A Young; Ramon C Sun; James R Pauly; Nadine M Aziz; Bradley L Hodges; Tracy R McKnight; Dustin D Armstrong; Matthew S Gentry
Journal:  Cell Metab       Date:  2019-07-25       Impact factor: 27.287

3.  Central Nervous System Delivery and Biodistribution Analysis of an Antibody-Enzyme Fusion for the Treatment of Lafora Disease.

Authors:  Grant L Austin; Zoe R Simmons; Jack E Klier; Alberto Rondon; Brad L Hodges; Robert Shaffer; Nadine M Aziz; Tracy R McKnight; James R Pauly; Dustin D Armstrong; Craig W Vander Kooi; Matthew S Gentry
Journal:  Mol Pharm       Date:  2019-08-02       Impact factor: 4.939

Review 4.  [Lafora disease: a review of the literature].

Authors:  L Desdentado; R Espert; P Sanz; J Tirapu-Ustarroz
Journal:  Rev Neurol       Date:  2019-01-16       Impact factor: 0.870

5.  Discovery and Development of Small-Molecule Inhibitors of Glycogen Synthase.

Authors:  Buyun Tang; Mykhaylo S Frasinyuk; Vimbai M Chikwana; Krishna K Mahalingan; Cynthia A Morgan; Dyann M Segvich; Svitlana P Bondarenko; Galyna P Mrug; Przemyslaw Wyrebek; David S Watt; Anna A DePaoli-Roach; Peter J Roach; Thomas D Hurley
Journal:  J Med Chem       Date:  2020-03-23       Impact factor: 7.446

Review 6.  The role of autophagy in epileptogenesis and in epilepsy-induced neuronal alterations.

Authors:  Filippo Sean Giorgi; Francesca Biagioni; Paola Lenzi; Alessandro Frati; Francesco Fornai
Journal:  J Neural Transm (Vienna)       Date:  2014-09-14       Impact factor: 3.575

7.  Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease.

Authors:  Arnaud Berthier; Miguel Payá; Ana M García-Cabrero; Maria Inmaculada Ballester; Miguel Heredia; José M Serratosa; Marina P Sánchez; Pascual Sanz
Journal:  Mol Neurobiol       Date:  2015-01-28       Impact factor: 5.590

Review 8.  The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.

Authors:  Alessandro Orsini; Angelo Valetto; Veronica Bertini; Mariagrazia Esposito; Niccolò Carli; Berge A Minassian; Alice Bonuccelli; Diego Peroni; Roberto Michelucci; Pasquale Striano
Journal:  Seizure       Date:  2019-08-23       Impact factor: 3.184

Review 9.  Lafora disease - from pathogenesis to treatment strategies.

Authors:  Felix Nitschke; Saija J Ahonen; Silvia Nitschke; Sharmistha Mitra; Berge A Minassian
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

10.  Efficacy and tolerability of perampanel in ten patients with Lafora disease.

Authors:  Danielle Goldsmith; Berge A Minassian
Journal:  Epilepsy Behav       Date:  2016-07-25       Impact factor: 2.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.